NEW YORK (GenomeWeb) – Metabolon announced today that it has signed a deal to commercialize its Quantose IR insulin resistance test in 30 international markets with European clinical laboratory network Synlab.

Quantose IR is a blood-based test uses insulin and three non-glycemic biomarkers to assess the risk of a patient developing prediabetes. Under the terms of the arrangement, Synlab will introduce the test first in Spain and then in other markets throughout Europe, Latin America, and the Middle East during 2016.

Additional terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.